Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

Abstract:

:Glatiramer acetate is a synthetic analogue of the multiple sclerosis (MS)-associated antigen, myelin basic protein. It is indicated in the EU, US and many other countries to reduce the frequency of relapses in patients with relapsing-remitting MS (RRMS), and for the treatment of patients who have experienced a well defined first clinical episode and are at high risk of developing clinically definite MS or have features of MS on MRI. The efficacy of glatiramer acetate in patients with RRMS has been shown in two randomized, double-blind, multicentre phase III trials. In one trial, glatiramer acetate was associated with a significantly lower mean relapse rate than placebo after 24 months' treatment (primary endpoint). In an ongoing open-label extension to this trial, glatiramer acetate was associated with a sustained reduction in the relapse rate at the 6-, 8- and 15-year follow-ups. In the other trial, the mean cumulative number of gadolinium-enhancing lesions on T1-weighted MRI images was significantly lower in glatiramer acetate versus placebo recipients after 9 months' treatment (primary endpoint). Glatiramer acetate also had generally similar efficacy to subcutaneous interferon (IFN)-beta-1a or IFNbeta-1b in two large randomized, open-label, multicentre phase III trials conducted over 96 weeks or >or=2 years. These data were supported by those from a smaller randomized, open-label phase IV trial that utilized a unique imaging protocol to evaluate the efficacy of glatiramer acetate versus that of IFNbeta-1b over >or=2 years. In these trials, there was no significant difference between glatiramer acetate and IFNbeta recipients in any of the clinical endpoints at study end (e.g. time to first relapse [primary endpoint of the REGARD trial] or risk of relapse [primary endpoint of the BEYOND trial]). Moreover, there was no significant difference between glatiramer acetate and IFNbeta-1b recipients in the median number of combined active lesions per patient per monthly MRI scan during the first 12 months of treatment (primary endpoint of the BECOME trial). In general, there was no significant between-group difference in the majority of other MRI-assessed endpoints in any of the trials. The efficacy of glatiramer acetate in patients with clinically isolated syndrome (CIS) was established in a randomized, double-blind, double-dummy, multicentre phase III trial (the PreCISe trial). In this study, glatiramer acetate was associated with a significantly longer time to conversion to clinically definite MS than placebo (primary endpoint). Glatiramer acetate was generally well tolerated in clinical trials, with most adverse events being mild to moderate in severity. Injection site-related reactions and immediate post-injection systemic reactions were the most frequently observed adverse events associated with glatiramer acetate in clinical studies. In conclusion, glatiramer acetate is a valuable first-line option in the treatment of RRMS, as well as being an option in the treatment of CIS.

journal_name

Drugs

journal_title

Drugs

authors

Carter NJ,Keating GM

doi

10.2165/11204560-000000000-00000

subject

Has Abstract

pub_date

2010-08-20 00:00:00

pages

1545-77

issue

12

eissn

0012-6667

issn

1179-1950

pii

5

journal_volume

70

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00042

    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • Prediction of response to cancer chemotherapy.

    abstract::Cytotoxic chemotherapy plays a key role in the treatment of carcinoma for thousands of patients annually who either present with metastatic disease or relapse after surgical excision of apparently localised disease. Unfortunately, there is such a wide range of responsiveness to drug therapy within individual tumour ty...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198326050-00004

    authors: Sarosdy MF,Von Hoff DD

    更新日期:1983-11-01 00:00:00

  • New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity.

    abstract::In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin(®) was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0277-6

    authors: Mohty M,Bacigalupo A,Saliba F,Zuckermann A,Morelon E,Lebranchu Y

    更新日期:2014-09-01 00:00:00

  • Correction to: Deprescribing Opioids in Chronic Non‑cancer Pain: Systematic Review of Randomised Trials.

    abstract::Page 9, Fig. 2, which originally appeared as. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01416-7

    authors: Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

    更新日期:2020-10-01 00:00:00

  • Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.

    abstract::Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disease that ultimately leads to disability and functional decline. Because patients usually develop RA in mid-life, they may experience its consequences for 20-30 years or longer. Proinflammatory cytokines, notably interleukin (IL)-1 and tumour necro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464220-00001

    authors: Schiff MH

    更新日期:2004-01-01 00:00:00

  • Hypopigmentary skin disorders: current treatment options and future directions.

    abstract::Alterations of skin and hair pigmentation are important features that have warranted treatment from ancient history on up to modern time. In some cultures, even today patients with vitiligo are regarded as social outcasts and are affected considerably both emotionally and physically. This article presents current opti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464010-00006

    authors: Hartmann A,Bröcker EB,Becker JC

    更新日期:2004-01-01 00:00:00

  • Microbiological evaluation of cefpodoxime proxetil.

    abstract::Cefpodoxime, the active de-esterified molecule of the orally absorbable cephalosporin cefpodoxime proxetil, inhibits streptococci, Neisseria spp., and most Enterobacteriaceae, with MIC50 and/or MIC90 values of less than or equal to 2 mg/L; with regard to the latter family of bacteria, the MIC50 and/or MIC90 values of ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199100423-00004

    authors: Wiedemann B,Luhmer E,Zühlsdorf MT

    更新日期:1991-01-01 00:00:00

  • HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

    abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666020-00002

    authors: Laufs U,Custodis F,Böhm M

    更新日期:2006-01-01 00:00:00

  • Nivolumab: a review of its use in patients with malignant melanoma.

    abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0234-4

    authors: Deeks ED

    更新日期:2014-07-01 00:00:00

  • Antiarrhythmic therapies for the prevention of sudden cardiac death.

    abstract::Despite remarkable advances in cardiovascular therapeutics, sudden cardiac death remains a significant problem. In this review, data from clinical trials and other studies on antiarrhythmic therapies have been evaluated in order to determine effective strategies for the prevention of sudden cardiac death in high risk ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754020-00003

    authors: McAlister FA,Teo KK

    更新日期:1997-08-01 00:00:00

  • Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

    abstract::Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), has identical biological activity to that of endogenous human G-CSF, but differs in that it contains an N-terminal methionine residue and is not glycosylated. It principally stimulates activation, proliferation and differentiation of neutro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448050-00007

    authors: Frampton JE,Lee CR,Faulds D

    更新日期:1994-11-01 00:00:00

  • The polyol pathway. A historical review.

    abstract::Polyhydric alcohols (polyols) are widely distributed in nature, and the enzymes of the polyol pathway (aldose reductase and sorbitol dehydrogenase) are present in many mammalian tissues. The function of this pathway remains a mystery. A primary role for the pathway in the pathogenesis of 'sugar cataract' was provided ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600322-00003

    authors: Clements RS Jr

    更新日期:1986-01-01 00:00:00

  • The diuretic dilemma and the management of mild hypertension.

    abstract::Diuretics are used in first-step antihypertensive monotherapy or in combination with adrenergic-inhibiting agents in the majority of hypertensive patients in the United States. A 30-year experience has demonstrated that blood pressure is lowered to as great or greater a degree with diuretics than when many of the pres...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600314-00007

    authors: Moser M

    更新日期:1986-01-01 00:00:00

  • [Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

    abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856002-00004

    authors: Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

    更新日期:1998-01-01 00:00:00

  • Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.

    abstract::Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity excee...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0541-z

    authors: Blair HA,Keating GM

    更新日期:2016-03-01 00:00:00

  • Sotagliflozin: A Review in Type 1 Diabetes.

    abstract::Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01230-w

    authors: Deeks ED

    更新日期:2019-12-01 00:00:00

  • Suvorexant: first global approval.

    abstract::Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0294-5

    authors: Yang LP

    更新日期:2014-10-01 00:00:00

  • Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function.

    abstract::Because of inappropriate signals from the volume-regulation system and a reduction in renal blood flow, the kidney is not able to prevent sodium and water retention in chronic congestive heart failure (CHF). A brief summary of normal renal function and renal involvement in CHF is given and a study of renal function in...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199000394-00004

    authors: Ljungman S,Laragh JH,Cody RJ

    更新日期:1990-01-01 00:00:00

  • Current concepts in diabetic gastroparesis.

    abstract::Diabetic gastroparesis is a common and debilitating condition affecting millions of patients with diabetes mellitus worldwide. Although gastroparesis in diabetes has been known clinically for more than 50 years, treatment options remain very limited. Until recently, the scientific literature has offered few clues rega...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363130-00002

    authors: Smith DS,Ferris CD

    更新日期:2003-01-01 00:00:00

  • Drugs and receptors. An overview of the current state of knowledge.

    abstract::This paper reviews the theoretical concepts and methods utilised with isolated tissues to characterise drugs and drug receptors. Specifically the impact, on the in vitro measurement of agonist affinity and relative efficacy, of the idea that receptors bind to transduction proteins in the lipid bilayer of the cell memb...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040050-00003

    authors: Kenakin T

    更新日期:1990-11-01 00:00:00

  • Zaleplon: a review of its use in the treatment of insomnia.

    abstract::Zaleplon is a pyrazolopyrimidine hypnotic agent which is indicated for the short term (2 to 4 weeks) management of insomnia. Zaleplon 5 and 10 mg at bedtime (usual recommended doses) significantly reduced sleep latency compared with placebo in clinical trials in nonelderly and elderly patients with insomnia. In genera...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060020-00014

    authors: Dooley M,Plosker GL

    更新日期:2000-08-01 00:00:00

  • Eravacycline: A Review in Complicated Intra-Abdominal Infections.

    abstract::Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01067-3

    authors: Scott LJ

    更新日期:2019-02-01 00:00:00

  • The role of anaerobic bacteria in mediastinitis.

    abstract::The management of mediastinitis involves directing appropriate antibacterial therapy against the potential bacterial pathogens. The increased recovery of anaerobic bacteria from mediastinal infections has led to a greater appreciation of their role in this condition and to re-evaluation of the proper treatment of this...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666030-00004

    authors: Brook I

    更新日期:2006-01-01 00:00:00

  • Pimavanserin: First Global Approval.

    abstract::Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0597-9

    authors: Markham A

    更新日期:2016-07-01 00:00:00

  • Current options in the treatment of non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in industrialised countries, with an overall 5-year survival rate of less than 10%. Good patient performance status is associated with a significantly improved prognosis, whereas the presence of metastases, particularly to the bone or liver, is asso...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199200444-00006

    authors: Faulds D

    更新日期:1992-01-01 00:00:00

  • Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure.

    abstract::The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198500301-00011

    authors: Webster MW,Fitzpatrick MA,Hamilton EJ,Nicholls MG,Ikram H,Espiner EA,Wells JE

    更新日期:1985-01-01 00:00:00

  • Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.

    abstract::Non-24-h sleep-wake disorder (non-24) is a circadian rhythm disorder occurring in 55-70% of totally blind individuals (those lacking conscious light perception) in which the 24-h biological clock (central, hypothalamic, circadian pacemaker) is no longer synchronized, or entrained, to the 24-h day. Instead, the overt r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0707-3

    authors: Emens JS,Eastman CI

    更新日期:2017-04-01 00:00:00

  • Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.

    abstract::Utilising a modified fixed-dose, 4 x 3 factorial design, the antihypertensive effects of all combinations of 4 doses of pinacidil (0, 12.5, 25 and 37.5 mg bid) with 3 doses of hydrochlorothiazide (0, 12.5 and 25 mg bid) were studied in patients with supine diastolic blood pressure of 95 to 110mm Hg. The decreases in s...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800367-00015

    authors: Goldberg MR,Offen WW

    更新日期:1988-01-01 00:00:00

  • Effects of ketanserin tartrate on serum lipids in patients with essential hypertension.

    abstract::Several antihypertensive agents such as thiazide diuretics and some beta-blockers have recently been shown to adversely affect lipid metabolism. Moreover, there is a growing suspicion that the adverse effect on plasma lipids might outweigh the favourable effect of lowering blood pressure. The effect of ketanserin tart...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198800361-00006

    authors: Nakamura H,Hirata F,Yasugi T,Mizuno M,Saito E,Ishikawa T,Tada N,Nakaya N,Homma Y,Takeuchi I

    更新日期:1988-01-01 00:00:00

  • Vaccination strategies in lymphomas and leukaemias: recent progress.

    abstract::The successful identification of a range of leukaemia-specific and lymphoma-specific antigens in recent years has stimulated efforts to develop therapeutic vaccination strategies. A number of clinical trials have established the safety and immunogenicity of vaccination against tumour antigens, although there are limit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11593270-000000000-00000

    authors: Rezvani K,de Lavallade H

    更新日期:2011-09-10 00:00:00